MOLECULAR PARTNERS AG MOLN 深 沪
已收盘 07-18 16:00:00 美东时间
3.595
-0.055
-1.51%
华盛通- 最 高3.595
- 今 开3.595
- 成交量 408股
- 最 低 3.595
- 昨 收 3.65
- 总市值 1.33亿
- 52周最高 12.22
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.36
- 委 比 34.64%
- 总股本 3687.46万
- 历史最高 32.04
- 量 比 0.41
- 振 幅 0.00%
- 历史最低 3.32
- 每 手 1
- 风险率 0.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships
Moleculin Biotech, Inc. appoints Adriano Treve as a Strategic Advisor to enhance partnerships and advance its Phase 2B/3 MIRACLE trial for Annamycin in treating relapsed or refractory acute myeloid leukemia (AML). With over 40 years of experience at Roche, Treve brings expertise in global healthcare and market access. Moleculin expects his insights to strengthen strategic collaborations and accelerate development of key partnerships, aiming to cr...
07-17 12:25
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025
Molecular Partners and Orano Med announce MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) for ovarian cancer treatment. Preclinical data show high tumor accumulation (up to 34%) and favorable biodistribution. The collaboration aims to advance innovative Radio-DARPin therapies leveraging MSLN targeting, addressing unmet medical needs for cancer patients. MP0726 follows MP0712, another Radio-DARPin candidate targeting DLL3, poised to b...
06-22 20:00
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025
Three of eight R/R AML patients responded after cycle 1 in cohort 8, with one maintaining response beyond 6 months. Cohort 8 utilized a steeper dosing regimen, achieving target dose by day 12 versus day 15 previously. MP0533 demonstrated acceptable safety and encouraging responses, leading to further dose optimization in ongoing cohort 9. Data support potential for increased therapeutic benefit with the new dosing scheme.
06-11 20:00
Moleculin Participates in Virtual Investor “What This Means” Segment
Moleculin Biotech participated in a Virtual Investor segment discussing positive topline results from its U.S. Phase 1B/2 clinical trial (MB-107) evaluating Annamycin for treating Soft Tissue Sarcoma Lung Metastases. Brian Andrew Van Tine, MD, PhD, highlighted the trial's success in determining the Maximum Tolerable Dose and safety, as well as exploring Annamycin's efficacy as a single agent. Moleculin focuses on developing therapies for hard-to-...
06-11 13:15
Molecular Partners To Cut Up To 40 Jobs In Strategic Review, Extends Cash Runway Into 2028
Guidance confirmed for clinical milestones for MP0533 and MP0712 in H2 2025Cash reach now anticipated to extend into 2028
06-10 13:48
Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway
Swiss biotech firm Molecular Partners intends to cut up to 40 positions (~24% of its workforce) to improve efficiency and focus on advancing its clinical assets MP0533 and MP0712, with clinical milestones expected in H2 2025. The company anticipates its cash runway extending into 2028, supporting both asset development and new product pipeline advancement. The workforce reduction, which will be fully implemented by end-2025, aims to secure the co...
06-10 05:00
Molecular Partners reports Q1 results
Molecular Partners AG press release (OTCPK:MLLCF): Q1 GAAP EPS of -CHF 0.45. For the full year 2025, at constant exchange rates, the company expects total operating expenses of CHF 55M-65M of which ar...
05-16 17:43
Molecular Partners Q1 EPS $0.51
Molecular Partners (NASDAQ:MOLN) reported quarterly earnings of $0.51 per share.
05-16 05:18
美股大行评级 | 美银证券：维持雅培"买入"评级，目标价从133美元升至150美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1106501041932570625.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Roth MKM：维持CervoMed Inc.(CRVO)"买入"评级，目标价从7美元升至15美元</p> <p>• Oppenheimer：维持Trevi Therapeutics(TRVI)"跑赢大市"评级，目标价从
03-12 11:01
Molecular Partners AG: Strategic Advances and Financial Overview
Molecular Partners Ag ( ($MOLN) ) has released its Q4 earnings. Here is a break...
03-08 11:53
